VEGF-C Binding Polypeptide for Inhibiting Lymphangiogenesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-angiogenesis therapies targeting VEGF-C are not sufficiently effective in inhibiting lymphangiogenesis and cancer metastasis, highlighting a need for more potent VEGF-C targeting drugs.
Innovation Solution
A polypeptide specifically binding to VEGF-C, functioning as a complementarity determining region of an anti-VEGF-C antibody, is developed to inhibit VEGF-C's angiogenic activity by preventing its binding to VEGFR2 or VEGFR3, along with an anti-VEGF-C antibody or antigen-binding fragment for therapeutic and diagnostic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional anti-angiogenesis therapies targeting VEGF-C are used, then some inhibition of angiogenesis is achieved, but the effectiveness in inhibiting lymphangiogenesis and cancer metastasis is insufficient
Solution Approach 1:
The patent modifies the binding affinity parameter of VEGF-C targeting agents by developing antibodies and fragments with optimized complementarity determining regions (CDRs) that enhance specific binding to VEGF-C, thereby increasing the potency and effectiveness of the therapy
Solution Approach 2:
The patent extracts and isolates specific functional regions (complementarity determining regions) from the antibody structure that are responsible for VEGF-C binding, and uses these extracted regions to create potent anti-VEGF-C agents that can effectively inhibit lymphangiogenesis and cancer metastasis
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polypeptide effectively inhibits lymphangiogenesis and cancer metastasis by blocking VEGF-C's interaction with its receptors, offering a more potent approach to treating diseases associated with VEGF-C overexpression.
Implementation Method 1
A polypeptide specifically binding to VEGF-C, functioning as a complementarity determining region of an anti-VEGF-C antibody, is developed to inhibit VEGF-C's angiogenic activity by preventing its binding to VEGFR2 or VEGFR3
Data Source
AI summary
An antibody or antigen-binding fragment thereof that specifically binds to and inhibits VEGF-C and uses thereof in a method of inhibiting angiogenesis and a method of preventing, treating, and/or diagnosing a disease associated with activation and/or overexpression of VEGF-C, using the antibody, and a method of detecting the presence of VEGF-C in a sample.